Contact us
About us
CareersPartnering
Pipeline
SCIENCE
BiTAC TechnologyBiTAC TCEsADC TechnologyFunctional Antibody Screening
INVESTORS
Voyager transactionPress ReleasesEvents & ConferencesScientific Publications
Contact Us
About us
Careers
Partnering
Pipeline
Science
BiTAC platform
BiTAC TCEs
ADC technologies
Functional antibody screening
Investors
Voyager transaction
Press releases
Events & conferences
Scientific publications
Contact Us
ImprintPrivacy policy
News & EventsPress Release

Press Release

May 20, 2025

VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

Industry veteran to support acceleration of key pipeline projects and novel BiTAC antibody formats towards clinical studies.

Read more
May 5, 2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program

The partnership combines VERAXA's proprietary ADC technology with OmniAb's antibody discovery technology for novel therapies targeting solid tumors.

Read more
April 23, 2025

‍VERAXA and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.

Read more